Catherine is a patient-centric leader with more than 20 years’ experience as an executive in startup and mid-size Pharma/Biotech companies. She was CEO & Founder of Nezee Therapeutics, served as President and R&D head for Novus Therapeutics, and served as Vice President & Global Development Team Leader at Allergan.
Dr. Turkel has formulated registration and commercial strategic plans and has led global development programs for pharmaceutical and biologic treatments from phase 1 through phase 4 related to Neurosciences, Pain, Cardiovascular, Psychiatry, Rare Diseases, Ophthalmology, Aesthetics, Urology and Otology therapeutic areas. She is passionate about development of innovative new treatments for patients with unmet needs.
She currently serves as an independent Board Director for Object Pharma, Inc (private firm) and Prostate Cancer Research (PCR-US), Inc (nonprofit). She also serves as a member of PCR-UK Translational Scientific Advisory Committee and Chapman University School of Pharmacy Dean's Professional Advisory Committee.